We're investing in a future where bioengineering has industrial scale and speed, and today’s barely conceivable medicines are routine.
Investment Stage: Series B
Portfolio 52
| Date | Name | Website | Total Raised | Location |
| 10.02.2026 | CORXEL Pha... | corxelbio.com | $287M | - |
| 17.12.2025 | SanegeneBi... | sanegenebio.com | $110M | China |
| 16.12.2025 | Aeovian Ph... | aeovian.com | $105M | United Sta... |
| 18.11.2025 | Solve Ther... | solvetx.com | $120M | - |
| 02.11.2025 | TORL | torlbio.com | $158M | United Sta... |
| 02.11.2025 | Alebund Ph... | alebund.com | - | China, Sha... |
| 26.03.2025 | Tempero Bi... | temperobio.com | $70M | United Sta... |
| 26.03.2025 | F2G | f2g.com | $291M | United Kin... |
| 11.03.2025 | Paradox Im... | paradoximmuno.com | $10M | - |
| 13.02.2025 | AdvanCell ... | advancell.com.au | $142.55M | Australia,... |
Show more
Persons 12
| Date | First Name | Last Name | Title | Location | |||
| - | Sarah | Hernandez | Administra... | - | - | - | |
| - | Caleb | Kreutner | Vice Presi... | - | - | - | |
| - | Brendon | Dobbs | Associate,... | - | - | - | |
| - | Ramona | Mullen | Chief of S... | - | - | - | |
| - | Catherine | Shoults, P... | Vice Presi... | - | - | - | |
| - | Trevor | Goethe | Analyst, O... | - | - | - | |
| - | Allie | Ivy, PhD | Analyst, I... | - | - | - | |
| - | Tony | Khoury | Operating ... | - | - | - | |
| - | Danny | Foody | Operating ... | - | - | - | |
| - | Geraldine | Schott, Ph... | Associate,... | - | - | - |
Show more
Mentions in press and media 10
| Date | Title | Description |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding. Backers included new investors includi... |
| 28.12.2025 | Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment | Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets seve... |
| 16.12.2025 | Aeovian Pharmaceuticals Raises $55M in Funding | Aeovian Pharmaceuticals, a Berkeley, CA-based clinical-stage biopharmaceutical company, raised $55M in funding. The round was led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Allianc... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 07.02.2023 | HEALTHTECH ARKANSAS AND KX ADVISORS PARTNER TO PROVIDE GROWTH STRATEGY SERVICES TO THE BIOAR TRIAL ACCELERATOR PARTICIPANTS | HealthTech Arkansas and Kx Advisors have partnered to provide support to the biotherapeutics startup companies participating in the BioAR Trial accelerator program. Kx Advisors provides advisory services to help leading pharmaceutical, biot... |
| 20.12.2022 | HEALTHTECH ARKANSAS AND LAINA ENTERPRISES PARTNER TO PROVIDE CLINICAL TRIAL SOFTWARE TO THE BIOAR TRIAL ACCELERATOR PARTICIPANTS | HealthTech Arkansas and Laina Enterprises have partnered to provide support to the biotherapeutics startup companies that participate in the BioAR Trial accelerator program. Laina Enterprises offers an end-to-end solution for Clinical Resea... |
| 20.10.2022 | HealthTech Arkansas and SymBiosis Form BioAR Trial Accelerator | HealthTech Arkansas and SymBiosis have come together to create BioAR Trial, an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasin... |
| 19.07.2022 | Christie’s tries its hand at venture capital | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It all started with the Picasso of pixels. Yes, I’m talking about Beeple. As you may recall, the ... |
| 27.10.2021 | SymBiosis Capital Management Launches To Invest in Advancing Biotherapeutics Innovations | Bentonville, Ark.-based SymBiosis Capital Management, LLC has launched as a newly independent venture capital firm focused on advancing biotherapeutics innovations. Investing since 2019, SymBiosis has received long-term capital commitments ... |
| 26.10.2021 | SymBiosis Capital Management Launches to Advance Extensive and Growing Biotherapeutics Innovations | SymBiosis Capital Management, LLC (“SymBiosis”) today announced its launch as a newly independent venture capital firm focused on advancing biotherapeutics innovations. Investing since 2019, SymBiosis has received significant, long-term cap... |